Matthew N. Gumbleton

Oncology

1950 Circle Of Hope Dr
Salt Lake City, UT 84112

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.

HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.

Journal: The Journal of clinical investigation

Published: May 12, 2026

HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.

HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.

Journal: The Journal of clinical investigation

Published: July 22, 2025

HNF4α controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung.

HNF4α controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.

Journal: bioRxiv : the preprint server for biology

Published: July 14, 2025

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult.

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult.

Journal: JAAD case reports

Published: September 16, 2024

Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer.

Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer.

Journal: Clinical lung cancer

Published: May 01, 2024

TTF-1 and immune checkpoint therapy in non-small cell lung cancer.

TTF-1 and immune checkpoint therapy in non-small cell lung cancer.

Journal: Translational lung cancer research

Published: February 12, 2023

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).

Journal: BMC research notes

Published: July 12, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026